Restoret (EYE103/MK-3000): A Novel Wnt Pathway Agonist for Retinal Diseases

I. Introduction

Restoret is an investigational therapeutic agent currently under development for the treatment of debilitating retinal vascular diseases. Spearheaded by EyeBiotech Ltd., now a subsidiary of Merck & Co., Inc., Restoret, also identified by the developmental codes EYE103 and MK-3000, represents a novel approach targeting primarily diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD).[1] Its distinction lies in its mechanism of action, which involves the activation of the Wingless-related integration site (Wnt) signaling pathway, a departure from existing therapeutic strategies predominantly focused on vascular endothelial growth factor (VEGF) inhibition.[1] This report provides a comprehensive overview of Restoret, detailing its identity, mechanism, therapeutic indications, clinical development program, efficacy and safety findings, pharmacokinetic considerations, and regulatory outlook.

II. Drug Identity and Manufacturer

A. Name

The investigational drug is known as Restoret™. Its developmental codenames include EYE103 and, following its acquisition by Merck, MK-3000.[1] It is crucial to distinguish Restoret from "Restoril," a brand name for temazepam, which is a benzodiazepine medication used for insomnia and is entirely unrelated to this ophthalmic therapeutic.[5]

B. Manufacturer

Restoret was initially developed by EyeBiotech Limited (EyeBio).[7] In a significant strategic move, Merck & Co., Inc. (known as MSD outside the United States and Canada) completed the acquisition of EyeBio, making EyeBio a wholly-owned subsidiary of Merck. This acquisition has integrated Restoret into Merck's late-stage pipeline.[1]

C. Drug Class and Type

Restoret is classified as an ophthalmic agent intended for the treatment of retinal diseases. From a molecular perspective, it is a sophisticated biologic, specifically engineered as a humanized antibody.[9] More precisely, Restoret is a tetravalent, tri-specific antibody construct based on an IgG1 framework.[1] This complex structure allows it to interact with multiple targets or epitopes simultaneously, underpinning its unique mechanism of action.

III. Mechanism of Action

A. Target Pathway: Wnt Signaling Pathway

The primary target of Restoret is the Wnt signaling pathway, a highly conserved signaling cascade crucial for embryonic development and adult tissue homeostasis, including the maintenance of vascular integrity within the retina.[3] In the eye, Wnt signaling plays a pivotal role in establishing and preserving the blood-retinal barrier (BRB), a critical structure that regulates the passage of fluids and molecules into the retina.[1] Defects or dysregulation in the Wnt pathway can lead to increased vascular permeability and leakage, hallmarks of diseases like DME and NVAMD.[12] Restoret is designed to act as an agonist of this pathway, thereby aiming to restore normal BRB function and reduce pathological leakage.[1]

B. Molecular Target: FZD4/LRP5 and WSPAR

Restoret is engineered to activate the Wnt pathway by mimicking the natural ligand Norrin. It is a tri-specific antibody that binds to the Frizzled-4 (FZD4) receptor and the Low-density lipoprotein receptor-related protein 5 (LRP5) co-receptor.[3] Specifically, its design as F4L5.13, a tetravalent antibody, induces proximity of FZD4 and LRP5 in a manner that triggers β-catenin signaling, a key downstream component of the canonical Wnt pathway.[10]

The molecule also interacts with WSPAR, which stands for "WNT signaling pathway activating non-coding RNA".[14] Some sources describe Restoret's action as a "WSPAR inhibitor".[14] This is not contradictory to its role as a Wnt agonist. WSPAR itself is understood to be an inhibitor of Wnt pathway activators (a "WNT signaling pathway activating non-coding RNA inhibitor").[14] Therefore, by inhibiting WSPAR, Restoret effectively removes a brake on the Wnt pathway, leading to its activation or agonism. This intricate interaction underscores the targeted nature of Restoret's design to modulate Wnt signaling precisely.

C. Therapeutic Effect

The intended therapeutic effect of Restoret is to stabilize retinal vasculature and reduce fluid accumulation in the retina. By agonizing the Wnt pathway, Restoret aims to restore and maintain the integrity of the BRB, thereby eliminating or reducing the vascular leakage that characterizes conditions like DME and NVAMD.[1] This mechanism offers a distinct therapeutic approach compared to current standards of care, such as anti-VEGF therapies, which primarily target the VEGF pathway to reduce neovascularization and permeability.[3] The novel mechanism of Wnt agonism holds the potential to address aspects of retinal vascular disease pathology not fully managed by anti-VEGF agents, possibly offering benefits to patients who have suboptimal responses to existing treatments or providing a complementary mode of action.

IV. Therapeutic Indications

A. Primary Investigated Indications

The primary focus of Restoret's clinical development is on two major retinal vascular diseases that are leading causes of vision loss:

Diabetic Macular Edema (DME): A complication of diabetes characterized by swelling in the macula due to leaky blood vessels.[1] DME affects a significant number of individuals with diabetes, estimated at 750,000 people in the United States alone.[2]
Neovascular Age-Related Macular Degeneration (NVAMD): Also known as wet AMD, this condition involves the growth of abnormal blood vessels under the retina, leading to leakage and vision distortion.[1]

B. Potential Future Indication: Familial Exudative Vitreoretinopathy (FEVR)

Beyond DME and NVAMD, Restoret is also listed with an active indication for Familial Exudative Vitreoretinopathy (FEVR).[14] FEVR is a rare, inherited disorder characterized by incomplete vascularization of the peripheral retina, which can lead to severe vision loss. The Wnt signaling pathway, particularly involving Norrin and its receptor FZD4, is critically implicated in the pathogenesis of FEVR, with mutations in these genes being known causes of the disease.[10] The strong mechanistic link between Wnt signaling and FEVR makes Restoret, as a Wnt agonist, a rational candidate for this condition. Pursuing FEVR could represent an orphan drug indication, potentially offering an accelerated regulatory pathway and addressing a significant unmet medical need in this patient population.

C. Rationale for Indications

The selection of DME, NVAMD, and potentially FEVR as therapeutic targets for Restoret is grounded in their shared underlying pathophysiology, which involves compromised vascular integrity and BRB dysfunction. Restoret's mechanism of action, aimed at restoring BRB function and reducing vascular leakage via Wnt pathway agonism, directly addresses these pathological processes.

V. Clinical Development Program

A. Overview of Clinical Trials

Restoret (EYE103/MK-3000) has progressed through several stages of clinical evaluation:

A Phase 1 study, which included a multiple ascending dose (MAD) portion (part 1 of the AMARONE trial), has been completed. This phase primarily assessed initial safety and tolerability at escalating doses.[7]
The Phase 1b/2a AMARONE trial (identified as NCT05919693 or EYE103-101) has also been completed. This two-part study evaluated safety and preliminary efficacy in patients with DME and NVAMD.[1]
Currently, Phase 2 studies are actively recruiting. One such study is registered under NCT06957080.[7]
A pivotal Phase 2b/3 trial, known as BRUNELLO (NCT06571045, also referred to as EYE-RES-102 in some contexts), has been initiated and is recruiting participants. This trial is designed to further evaluate the efficacy and safety of Restoret in patients with DME.[1]

The strategic progression of Restoret's clinical development, from initial safety assessments in Phase 1 to more extensive efficacy and safety evaluations in Phase 1b/2a (AMARONE), has laid the groundwork for the current large-scale pivotal Phase 2b/3 BRUNELLO trial. The positive data from the AMARONE study likely informed the design of the BRUNELLO trial, including dose selection and the primary focus on DME. Furthermore, Merck's decision to acquire EyeBio after the availability of Phase 1b/2a AMARONE results strongly signals confidence in Restoret's potential and the robustness of its early clinical data.[1]

B. Table 1: Key Clinical Trials for Restoret (EYE103/MK-3000)

Trial ID (Name, NCT #)	Phase	Status	Condition(s) Studied	Key Objectives/Endpoints	No. of Participants (Planned/Actual)	Intervention Arms	Comparator
AMARONE (EYE103-101, NCT05919693)	1b/2a	Completed	DME (monotherapy), NVAMD (in combination with aflibercept)	Safety, preliminary efficacy (mean change in BCVA from baseline to Week 12)	Up to 92 (planned) 8; 31 (actual for efficacy: 26 DME, 5 NVAMD) 12	EYE103 (multiple ascending doses, then 3 selected doses)	None (DME); Aflibercept (NVAMD as combo)
BRUNELLO (EYE-RES-102, NCT06571045)	2b/3	Recruiting	Diabetic Macular Edema (DME)	Safety, efficacy (mean change in BCVA from baseline to week 52)	Approx. 960 (target/planned) 7	EYE103/MK-3000 (low dose), EYE103/MK-3000 (high dose)	Ranibizumab 0.5 mg
"A Study of 2 Doses of EYE103" (NCT06957080)	2	Recruiting	Diabetic Macular Edema (DME)	Efficacy and safety of 2 doses of EYE103	960 (target) 7	EYE103 (Dose 1), EYE103 (Dose 2)	Ranibizumab 0.5 mg

Sources for Table 1: [1]

VI. Clinical Efficacy

A. AMARONE Trial (NCT05919693) Results (Week 12 Data)

The Phase 1b/2a AMARONE trial provided the first clinical insights into Restoret's efficacy. The 12-week data demonstrated promising outcomes in both DME and NVAMD patient cohorts:

DME Cohort (Restoret Monotherapy, n=26):
Patients receiving Restoret as a monotherapy experienced a mean improvement in Best-Corrected Visual Acuity (BCVA) of +11.2 letters from baseline.[3]
There was a corresponding mean reduction in retinal thickness, as measured by central subfield thickness (CST) on optical coherence tomography (OCT), of -143 µm.[12] Another report indicated a reduction in CST from approximately 500 µm to 350 µm by Week 12.[3]
NVAMD Cohort (Restoret in combination with aflibercept, n=5):
Patients in this smaller cohort, who received Restoret alongside aflibercept, showed a mean BCVA improvement of +6.8 letters.[3]
These patients also exhibited substantial reductions in CST, achieving levels below 300 µm within one month of treatment initiation.[3]

These early results were viewed positively, indicating both functional (visual acuity) and anatomical (retinal thickness) improvements.[3] The outcomes in the DME monotherapy arm are particularly noteworthy. Achieving a clinically significant improvement of +11.2 letters in BCVA and a substantial reduction in CST with a novel Wnt pathway agonist, without concomitant anti-VEGF therapy, provides the first clinical proof-of-concept for this mechanism in retinal vascular diseases.[3] This suggests that Restoret may offer a therapeutic benefit through a pathway distinct from VEGF inhibition, which could be highly valuable for patients and supports its continued development.

B. Table 2: Summary of Efficacy Outcomes from the AMARONE (NCT05919693) Trial (Week 12)

Indication	Patient Cohort	Number of Patients (n)	Outcome Measure	Result at Week 12
DME	Restoret monotherapy	26	Mean change in BCVA from baseline	+11.2 letters
DME	Restoret monotherapy	26	Mean change in CST from baseline (OCT)	-143 µm
NVAMD	Restoret in combination with aflibercept	5	Mean change in BCVA from baseline	+6.8 letters
NVAMD	Restoret in combination with aflibercept	5	Mean change in CST from baseline (OCT)	Reduction to <300 µm

Sources for Table 2: [3]

C. Expected Efficacy Endpoints for the BRUNELLO Trial (NCT06571045)

The ongoing Phase 2b/3 BRUNELLO trial is designed to provide more definitive evidence of Restoret's efficacy in DME.

The primary efficacy endpoint is the mean change in BCVA from baseline to week 52.[2]
Secondary outcomes are expected to include assessments of anatomical changes (such as CST measured by OCT), the durability of treatment effects (evaluated through a personalized treatment interval (PTI) regimen in the second year of the study), and other measures of visual function.[2]
A critical aspect of the BRUNELLO trial is its comparison against an active comparator, ranibizumab (an established anti-VEGF therapy), which will be essential for determining the relative efficacy of Restoret.[2]

The design of the BRUNELLO trial—being randomized, double-masked, active-controlled, with a 52-week primary endpoint—reflects the rigor typically associated with pivotal studies intended to support regulatory approval. Success in this trial, particularly demonstrating comparable or superior efficacy to ranibizumab, would represent a major advancement for Restoret. The inclusion of a PTI arm in the second year also thoughtfully addresses the important clinical consideration of treatment burden, aiming to determine if Restoret can maintain efficacy with potentially less frequent dosing over the long term.[2]

VII. Safety and Tolerability

A. AMARONE Trial (NCT05919693) Safety Profile (Week 12 Data)

Early safety data from the AMARONE trial have been favorable:

Restoret was reported to be well-tolerated by participants in both the DME monotherapy cohort and the NVAMD combination therapy cohort at the 12-week assessment point.[3]
Crucially, no drug-related adverse events (AEs) were reported.[12]
Similarly, no drug-related serious adverse events (SAEs) were observed.[12]
Across a total of 123 intravitreal injections administered during the trial, there were no reported instances of intraocular inflammation (IOI)..[325]

The absence of drug-related AEs, SAEs, and particularly the lack of intraocular inflammation in the AMARONE trial, represents a very positive early safety signal. This is especially significant for an intravitreally administered biologic agent, where ocular inflammation can be a major concern. Such a favorable safety profile at this stage is critical for justifying progression to larger and longer-duration clinical trials like BRUNELLO.

B. Administration Route: Intravitreal Injection (IVT)

Restoret is administered directly into the eye via intravitreal (IVT) injection.[1] This route of administration is standard for many therapies targeting retinal diseases as it delivers the drug directly to the site of action. While common, IVT injections carry inherent procedural risks, such as endophthalmitis, retinal detachment, and transient increases in intraocular pressure, which are routinely monitored in clinical trials.[9]

C. Safety Monitoring in Ongoing Trials (BRUNELLO)

Safety continues to be a primary focus in the ongoing BRUNELLO trial, where it is designated as a dual primary endpoint alongside efficacy.[2] Participants in this two-year study will undergo comprehensive monitoring for both ocular and systemic adverse events. The long-term safety data generated from the BRUNELLO trial will be pivotal for the overall risk-benefit assessment of Restoret.

VIII. Pharmacokinetics (Preliminary Insights)

A. Route of Administration and Drug Type

Restoret is delivered via intravitreal injection.[1] As a humanized, tetravalent, tri-specific antibody based on an IgG1 structure, its pharmacokinetic (PK) properties will be influenced by its large molecular size and complex architecture.[1]

B. Expected Ocular Pharmacokinetics

Detailed, specific pharmacokinetic data for EYE103/MK-3000 (e.g., Cmax, half-life in human vitreous, systemic exposure levels) are not extensively provided in the available information.[9] However, general principles applicable to intravitreally administered antibodies can offer some context:

Local delivery aims to maximize drug concentration at the target site within the eye while minimizing systemic exposure and potential systemic side effects.
Antibodies typically have a relatively long half-life in the vitreous humor compared to small-molecule drugs. For instance, bevacizumab, another monoclonal antibody administered intravitreally, was found to have a vitreous half-life of approximately 6.6 days in rabbits, illustrating the persistence of such molecules in the eye.[22]
Clearance of antibodies from the eye is thought to occur through both anterior routes (via aqueous humor turnover) and posterior routes (involving the retinal and choroidal circulation).
The complex structure of bispecific and multispecific antibodies, such as Restoret, can introduce unique pharmacokinetic challenges related to their absorption, distribution, metabolism, and excretion, potentially affecting their efficacy and safety profiles.[23]

There is currently a gap in publicly available, specific pharmacokinetic parameters for Restoret. Given its unique tetravalent, tri-specific structure (described as a Diabody-Fc-Diabody format in one source [10]), its ocular distribution, duration of target engagement, and systemic exposure levels may differ from those of standard monoclonal antibodies. Understanding these PK characteristics is vital for optimizing dosing strategies and ensuring safety. Such data are likely being systematically collected within the ongoing clinical trials, as PK/PD (pharmacokinetic/pharmacodynamic) sub-studies are common components of late-stage drug development, even if not explicitly listed as primary endpoints for trials like BRUNELLO. The personalized treatment interval (PTI) arm in the BRUNELLO study suggests an effort to tailor dosing frequency based on individual patient response, which is indirectly linked to the drug's PK/PD profile.[2]

C. Dosing Regimen in Clinical Trials

The dosing regimens used in clinical trials provide some indication of the anticipated duration of action:

In the AMARONE trial, Restoret was administered monthly for three months.[12]
In the BRUNELLO trial, participants will receive treatment every four weeks during the first year. In the second year, the dosing frequency will be adjusted based on a personalized treatment interval (PTI) algorithm.[2] This initial monthly dosing suggests an expected therapeutic effect lasting at least four weeks.

IX. Regulatory Status and Future Outlook

A. Current Regulatory Status

Restoret (EYE103/MK-3000) is currently an investigational drug candidate.[1] It has not yet received marketing approval from major regulatory authorities such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).[9] Therefore, it is not available for general clinical use outside of controlled research studies.

B. Projected Development Pathway

The successful completion of the pivotal Phase 2b/3 BRUNELLO trial (NCT06571045) represents the next critical milestone in Restoret's development pathway. Positive and robust results from this trial, demonstrating both efficacy and safety, would form the cornerstone of regulatory submissions, such as a Biologics License Application (BLA) to the FDA in the United States. While the 12-week data from the AMARONE trial were encouraging, regulatory agencies typically require longer-term efficacy data (often 9 months or more) for ophthalmic drugs targeting chronic retinal conditions.[19] The BRUNELLO trial's 52-week primary endpoint is designed to meet this requirement.

C. Potential Impact and Future Directions

If Restoret successfully navigates the final stages of clinical development and gains regulatory approval, it could offer a significant new therapeutic option for patients with DME and NVAMD. Its novel mechanism of action, Wnt pathway agonism, has the potential to address unmet medical needs, particularly for patients who do not respond optimally to, or cannot tolerate, existing anti-VEGF therapies.[8] Restoret might find its place as a monotherapy or as part of a combination treatment regimen, as was explored for NVAMD in the AMARONE trial.

The potential indication for FEVR, if pursued and validated through further clinical studies, could lead to an orphan drug designation.[14] This would not only address a critical unmet need in a rare and severe pediatric retinal disease but could also potentially benefit from incentives associated with orphan drug development.

Restoret is strategically positioned to potentially overcome some of the limitations associated with current anti-VEGF treatments, such as the burden of frequent injections or the proportion of patients who experience persistent disease activity. If the BRUNELLO trial demonstrates strong efficacy, particularly if it shows non-inferiority or superiority to ranibizumab, and/or a more durable treatment effect allowing for extended dosing intervals (as suggested by the PTI arm), Merck could possess a valuable new asset in its ophthalmology portfolio. The FEVR indication, while targeting a smaller patient population, offers a niche opportunity with a strong mechanistic rationale and the potential to establish Restoret as a therapy for genetic retinal diseases characterized by Wnt pathway dysregulation.[10] Merck's substantial investment through the acquisition of EyeBio underscores a strong belief in Restoret's therapeutic and market potential.[1]

X. Conclusion

Restoret (EYE103/MK-3000) is an innovative, investigational tetravalent, tri-specific antibody representing a novel therapeutic approach for retinal vascular diseases. Its unique mechanism of action centers on agonizing the Wnt signaling pathway, potentially via inhibition of WSPAR, with the goal of restoring blood-retinal barrier integrity and reducing pathological vascular leakage.

Early clinical findings from the Phase 1b/2a AMARONE trial have been promising, demonstrating encouraging efficacy in improving visual acuity and reducing retinal thickness in patients with both DME (as monotherapy) and NVAMD (in combination with aflibercept). Importantly, these early studies also indicated a favorable safety profile, with Restoret being well-tolerated and no instances of intraocular inflammation reported.

The ongoing pivotal Phase 2b/3 BRUNELLO trial is of critical importance. Its results will be instrumental in further establishing Restoret's efficacy and safety profile, particularly in comparison to an active comparator (ranibizumab), and in evaluating long-term outcomes and the potential for personalized treatment intervals.

Should Restoret continue to demonstrate positive results, it holds the potential to become a valuable future therapeutic option, offering a new mechanistic class for the treatment of common and vision-threatening conditions like DME and NVAMD. Furthermore, its development for rare genetic disorders such as FEVR could address a significant unmet medical need, solidifying its position as a potentially transformative agent in the field of ophthalmology.

XI. References

Works cited

Merck Completes Acquisition of EyeBio - Merck.com, accessed May 29, 2025, https://www.merck.com/news/merck-completes-acquisition-of-eyebio/
Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial ..., accessed May 29, 2025, https://www.merck.com/news/merck-and-eyebio-announce-initiation-of-phase-2b-3-clinical-trial-for-restoret-for-the-treatment-of-diabetic-macular-edema/
Charles C. Wykoff, MD, PhD: Phase 1b/2a Results on Restoret for DME, nAMD - HCPLive, accessed May 29, 2025, https://www.hcplive.com/view/charles-c-wykoff-md-phd-phase-1b-2a-results-on-restoret-for-dme-namd
MSD, EyeBio launch trial of Restoret for diabetic macular oedema, accessed May 29, 2025, https://www.clinicaltrialsarena.com/news/msd-eyebio-launch-trial/
Temazepam - Wikipedia, accessed May 29, 2025, https://en.wikipedia.org/wiki/Temazepam
Restoril (Temazepam): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed May 29, 2025, https://www.rxlist.com/restoril-drug.htm
Restoret | MedPath, accessed May 29, 2025, https://trial.medpath.com/drug/0f5ca6312b85c846
EyeBio Announces First Patients Dosed in Phase 1b/2 Trial of Restoret™ in Neovascular Age Related Macular Degeneration and Diabetic Macular Edema - Business Wire, accessed May 29, 2025, https://www.businesswire.com/news/home/20230614951729/en/EyeBio-Announces-First-Patients-Dosed-in-Phase-1b2-Trial-of-Restoret-in-Neovascular-Age-Related-Macular-Degeneration-and-Diabetic-Macular-Edema
EYE103: A Promising New Treatment for Eye Diseases - Clinical trials, accessed May 29, 2025, https://clinicaltrials.eu/inn/eye103/
MK-3000, EYE103, F4L5.13, ANT-39, Restoret™ Clinical Multispecific, Trispecific, Biparatopic - YAbS database, accessed May 29, 2025, https://db.antibodysociety.org/db0/619/
Design principles and therapeutic applications of novel synthetic WNT signaling agonists, accessed May 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11145361/
EyeBio announces positive data from first-in-human Ph1b/2a ..., accessed May 29, 2025, https://www.modernretina.com/view/eyebio-announces-positive-data-from-first-in-human-ph1b-2a-amarone-trial-of-restoret-for-dme-dvamd
A Norrin/Wnt surrogate antibody stimulates endothelial cell barrier function and rescues retinopathy - PubMed, accessed May 29, 2025, https://pubmed.ncbi.nlm.nih.gov/34105895/
Restoret - Drug Targets, Indications, Patents - Synapse, accessed May 29, 2025, https://synapse.patsnap.com/drug/61ecc7412aa543a88f31959dbc9f9953
Merck and EyeBio Initiate Phase 2b/3 Trial for Restoret™ in Diabetic Macular Edema Treatment - Patsnap Synapse, accessed May 29, 2025, https://synapse.patsnap.com/blog/merck-and-eyebio-initiate-phase-2b3-trial-for-restorettm-in-diabetic-macular-edema-treatment
Familial Exudative Vitreoretinopathies - Drugs, Targets, Patents, accessed May 29, 2025, https://synapse.patsnap.com/disease/475681e2433e4ed68a404248ff2040c0
Distribution of general development status category - YAbS database - The Antibody Society, accessed May 29, 2025, https://db.antibodysociety.org/db0/results_target?sort=-isotype_fc&page=35
Ongoing Clinical Trials | Tennessee Retina, accessed May 29, 2025, https://www.tnretina.com/research/non-enrolling-studies
EyeBio Phase 1/2 results - Bay Bridge Bio, accessed May 29, 2025, https://www.baybridgebio.com/blog/eyebio-update-feb-2024
Now Enrolling | Retina and Vitreous of Texas, accessed May 29, 2025, https://www.retinatexas.com/clinical-trials/now-enrolling/
Merck and EyeBio announce initiation of phase 2b/3 BRUNELLO trial evaluating MK-3000 for treatment of diabetic macular edema - Ophthalmology Times, accessed May 29, 2025, https://www.ophthalmologytimes.com/view/merck-and-eyebio-announce-initiation-of-phase-2b-3-brunello-trial-evaluating-mk-3000-for-treatment-of-diabetic-macular-edema
Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits - Dove Medical Press, accessed May 29, 2025, https://www.dovepress.com/article/download/7517
Mechanism of Action and Pharmacokinetics of Approved Bispecific Antibodies, accessed May 29, 2025, https://www.biomolther.org/journal/view.html?uid=1580&vmd=Full&
Restoret - Drug Targets, Indications, Patents - Patsnap Synapse, accessed May 29, 2025, https://synapse-patsnap-com.libproxy1.nus.edu.sg/drug/61ecc7412aa543a88f31959dbc9f9953?campaign_promotion=news_series
SUBSPECIALTY NEWS: Izervay FDA approval, ReST committee updates on Syfovre, and more. | Retinal Physician, accessed May 29, 2025, https://retinalphysician.com/issues/2023/september/subspecialty-news/

Restoret Advanced Drug Monograph

Generic Name